BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 2.95M
Average 4.85M
BCRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $98.69M rose 247.5% year over year, ahead of the -577.6% change in trailing-twelve-month EBITDA.
Context
- EBITDA amounted to 39.7% of revenue in FY2025, up 36.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$404.53M (-216.4%) for the fiscal year ending Dec 2026, a slowdown from the +2614.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $98.69M+114.1% QoQ
- Last fiscal yearDec 2025
- $347.65M+2614.3% YoY
- LTMJun 2026
- -$302.96M-577.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +247.5% | +64.5% | -183.0 pp |
| 1 year | +2614.3% | -216.4% | -2830.7 pp |
| 3-year CAGR | — | -11.1% | — |
| 5-year CAGR | +3.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 347.65M USD
- Year-over-year change
- +2614.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 347.65M | +2614.3% |
| FY2024 | 2024-12-31 | 12.81M | +111.0% |
| FY2023 | 2023-12-31 | (116.34M) | +19.1% |
| FY2022 | 2022-12-31 | (143.85M) | -18.2% |
| FY2021 | 2021-12-31 | (121.74M) | — |
EBITDA vs competitors
How BCRX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -577.6% is the lowest of 4, against a peer median of -15.5%.
- EBITDA amounts to 32.2% of revenue for BCRX, versus a peer median of 669.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$179.89M USD | -30.1% | — | — | |
| LTM Sep 2026 | -€184.94M EUR | -15.5% | — | — | |
| LTM Jun 2026 | -$302.96M USD | -577.6% | — | 32.2% | |
| LTM Mar 2026 | -$438.52M USD | +24.4% | — | 669.6% | |
| Peer median (excluding BCRX) | — | -15.5% | — | 669.6% | |
Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 157.17M | 270.83M | 331.41M | 450.71M | 874.84M |
| Cost of Revenue | 7.26M | 6.59M | 4.66M | 12.49M | 19.08M |
| Gross Profit | 149.91M | 264.23M | 326.75M | 438.23M | 855.76M |
| Gross Margin | 95.4% | 97.6% | 98.6% | 97.2% | 97.8% |
| Research & Development | 208.81M | 253.3M | 216.57M | 174.64M | 166.13M |
| Selling, General & Admin | 118.82M | 159.37M | 213.89M | 266.13M | 348.65M |
| Operating Expenses | 327.63M | 412.67M | 430.46M | 440.77M | 514.77M |
| Depreciation & Amortization | 777K | 1.44M | 1.66M | 1.25M | 1.39M |
| EBITDA | (121.74M) | (143.85M) | (116.34M) | 12.81M | 347.65M |
| EBITDA Margin | -77.5% | -53.1% | -35.1% | 2.8% | 39.7% |
| Operating Income | (177.72M) | (148.44M) | (103.71M) | (2.54M) | 340.99M |
| Operating Margin | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Interest Income | 62K | 5.13M | 15.78M | 14.75M | 10.67M |
| Interest Expense | 59.29M | 99.09M | 108.24M | 98.52M | 78.87M |
| Other Income / Expenses | (4.09M) | (95.95M) | (122.52M) | (84.41M) | (73.6M) |
| Income Before Tax | (181.81M) | (244.38M) | (226.23M) | (86.95M) | 267.39M |
| Pre-Tax Margin | -115.7% | -90.2% | -68.3% | -19.3% | 30.6% |
| Income Tax Expense | 2.25M | 2.73M | 310K | 1.93M | 3.53M |
| Net Income | (184.06M) | (247.12M) | (226.54M) | (88.88M) | 263.86M |
| Net Margin | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| EPS (Basic) | (1.03) | (1.33) | (1.18) | (0.43) | 1.26 |
| EPS (Diluted) | (1.03) | (1.33) | (1.18) | (0.43) | 1.21 |
| Weighted Avg Shares | 179.12M | 185.91M | 192.2M | 206.7M | 209.89M |
| Weighted Avg Shares (Diluted) | 179.12M | 185.91M | 192.2M | 206.7M | 218.58M |
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.